Current Clinical Trials
This is a study to understand how effective and safe the investigational study drug ABP 938 is compared to aflibercept (Eylea®), in the treatment of Wet AMD. The study drug is administered through an intravitreal (IVT) injection.
This trial is recruiting patients with Wet AMD in order to evaluate the efficacy and safety of RGX-314 Gene Therapy. The investigational drug (RGX-314) will be administered through surgery, and will be compared against a control group undergoing regular treatment of ranibizumab.
Learn more about Atmosphere by viewing their video here: rgx-314.com/sr/amd/e
Download information handout here: atmosphere-patient-handout.pdf
The purpose of this study is to assess the effects of ranibizumab delivered by a new eye implant (also known as the Port Delivery System with ranibizumab, or PDS) on participants with Wet AMD.
Learn more about Belvedere at their website at belvederexplained.com
Downloadable PDF: belvederepatientbrochure.pdf
The purpose of this study is to determine whether KSI-301 is safe and effective in the treatment of Wet AMD, compared with the standard treatment with aflibercept (also called Eylea®). KSI-301 is administered through an intravitreal injection in the eye.
This trial is recruiting patients with Wet AMD. The purpose of this study is to learn about the safety and tolerability of the study drug, CLS-AX, (axitinib injectable suspension), when given as a single dose suprachoroidal (SC) injection in patients with wet AMD after they have received 3 or more prior intravitreal (IVT) injections of anti-VEGF therapy.
This 52-week trial is recruiting patients with Wet AMD, in order to compare the efficacy, safety and immunogenicity of the investigational drug, SOK583A1 to Eylea®. SOK583A1 is administered through intravitreal (IVT) injections.
This 52-week trial is recruiting patients with Wet AMD. This Phase 3 study compares investigational drug, OPT-302 + Lucentis® in 4 week and 8 week dosing versus standard of care Lucentis® in 4 week dosing. These medications are administered through intravitreal (IVT) injections.
Learn more about Shore from this downloadable handout: shore-patient-handout.pdf
The purpose of this study is to determine whether KSI-301 is safe and effective in the treatment of Diabetic Macular Edema (DME), compared with the standard of care treatment aflibercept (also called Eylea®). KSI-301 is administered through an intravitreal injection in the eye.
The goal of this study is to determine whether KSI-301 is safe and effective as a treatment for moderately severe to severe NPDR. KSI-301 is an anti-VEGF drug injected into the eye that is designed to last for a longer time inside the eye. In this study, KSI-301 will be given every 6 months after a series of initial doses, and changes in DR severity and the rate of development of sight-threatening complications will be compared between people who do or do not receive KSI-301.
This trial is recruiting patients with NPDR/DME in a 10 week study. It will determine whether the study drug, GSK2798745, will decrease or stop the leaking from the blood vessels and reduce edema in the eye.
This Phase 2 trial is for patients with Diabetic Macular Edema (DME). It consists of two parts: Part A is a 6 month dose selection of THR-687 in newly-diagnosed DME; and Part B is an 8 month trial for newly-diagnosed and previously treated DME patients using THR-687 (at the dose selected from Part A) versus the standard of care, Eylea®.
This Phase 2 trial is for patients with Diabetic Macular Edema (DME). It uses the investigational drug THR-149 versus the standard of care, Eylea® over a 6 month trial.
This trial explores the relationship between the aqueous humor composition and multimodal retinal imaging in patients with either neovascular age-related macular degeneration (Wet AMD) OR diabetic macular edema (DME) in response to standard treatment, Eylea®.
This trial is recruiting panretinal photocoagulation (PRP) treated diabetic retinopathy (DR) patients with diabetic macular ischemia (DMI). The investigational drug is being tested in an escalated dose of BI765128 (mab in the anti-VEGF pathway) compared to a sham injection.
Geographic Atrophy (GA)
This trial is recruiting patients with Geographic Atrophy (GA) and features an oral administration of the study drug through a pill. The goal of this study is to evaluate the effect of different dosage regimens of danicopan on the progression of GA secondary to AMD compared to placebo.
This trial is recruiting patients with Geographic Atrophy (GA) who have never received treatment for their GA before. The investigational drug called ANX007 will be administered by intravitreal injection for subjects with GA due to age-related macular degeneration (AMD).
This trial is recruiting patients with Geographic Atrophy (GA). The purpose of this study is to test single doses of RO7303359 at different strengths to find out if it is safe and to understand the way the body processes the study drug. RO7303359 will be administered by intravitreal injection.
Ongoing, not recruiting
It is a 1 year trial, sponsored by NEI, assessing Avastin vs. Eylea for CRVO. This is designed as a non-inferiority trial in an effort to determine if Avastin is non-inferior to Eylea. Injections are given every 4 weeks followed by an adaptive treatment strategy where participants who were initially assigned to Eylea will be randomly reassigned to: Eylea every 4 weeks or Eylea on a treat and extend schedule. Those subjects in the Lucentis arm will then be re- randomized to: Lucentis every 4 weeks or Lucentis on a treat and extend schedule.